CNC Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

48.41B

+18.65%

-1.224

-252.99%

48.44B

+3.91%

2.068

-28.68%

48.06B

-1.4%

0.981

-713.39%

Estimates Revision

The market is revising Upward the revenue expectations for Centene Corporation (CNC) for FY2025, with the revenue forecasts being adjusted by 1.66% over the past three months. During the same period, the stock price has changed by 23.21%.

Revenue Estimates for FY2025

Revise Upward

+1.66%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+22.57%

In Past 3 Month

Stock Price

Go Up

+23.21%

In Past 3 Month

15 Analyst Rating

Wall Street analysts forecast CNC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNC is 39.23 USD with a low forecast of 32.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

9 Hold

2 Sell

Hold

Current: 0.000

Low

32.00

Averages

39.23

High

45.00

Current: 0.000

Low

32.00

Averages

39.23

High

45.00

Wells Fargo

Equal Weight

maintain

$35 -> $43

2026-01-07

New

Reason

Wells Fargo

Price Target

$35 -> $43

2026-01-07

New

maintain

Equal Weight

Reason

Wells Fargo raised the firm's price target on Centene to $43 from $35 and keeps an Equal Weight rating on the shares. For managed care organizations, the firm is most constructive on Medicare Advantage with uncertainty high for Medicaid/Exchanges. Wells sees a more difficult backdrop for hospitals in 2026 as post-COVID tailwinds wane and legislative risks near. Distributor debate remains revisions vs. multiples.

Bernstein

Lance Wilkes

Outperform

maintain

$45 -> $59

2026-01-06

New

Reason

Bernstein

Lance Wilkes

Price Target

$45 -> $59

2026-01-06

New

maintain

Outperform

Reason

Bernstein analyst Lance Wilkes raised the firm's price target on Centene to $59 from $45 and keeps an Outperform rating on the shares. The firm sees a sector turnaround in the government managed care organization sector beginning in 2026, but expects to see bumps in the recovery. Bernstein believes all MCO sectors present attractive entry points, with Medicare Advantage likely to see the nearest term earnings improvements and Medicaid representing the most attractive valuations.

Truist

Buy

downgrade

$47 -> $45

2026-01-05

New

Reason

Truist

Price Target

$47 -> $45

2026-01-05

New

downgrade

Buy

Reason

Truist lowered the firm's price target on Centene to $45 from $47 and keeps a Buy rating on the shares. While there remains uncertainty around Enhanced Advance Premium Tax Credits, expectations around an extension resolution are low, and the firm's estimates assume meaningful membership contraction in Marketplace in 2026 across its coverage universe, the analyst tells investors in a research note. Truist sees an attractive Medicare margin recovery opportunity in both Individual and Group given what a conservative utilization assumptions dialed into pricing following several years of strong trend, the attractive MA rate update, and the companies' focus on margin over growth aided by targeted initiatives including benefit adjustments, pricing and footprint rationalization.

BofA

Neutral

downgrade

$380 -> $360

2026-01-05

New

Reason

BofA

Price Target

$380 -> $360

2026-01-05

New

downgrade

Neutral

Reason

BofA lowered the firm's price target on Cencora to $360 from $380 and keeps a Neutral rating on the shares. Heading into 2026, the firm maintains its positive view on the drug distributor group and updates its price targets to reflect peer group multiple changes.

Barclays

Equal Weight -> Overweight

upgrade

$44 -> $54

2026-01-05

New

Reason

Barclays

Price Target

$44 -> $54

2026-01-05

New

upgrade

Equal Weight -> Overweight

Reason

Barclays upgraded Centene to Overweight from Equal Weight with a price target of $54, up from $44. The firm cites the company's "attractive" Affordable Care Act exchange margin upside for the upgrade. Barclays' ACA pricing analysis reinforces its confidence that Centene is best positioned to improve margins by "balancing strong absolute premium increases with stable competitive positioning," the analyst tells investors in a research note.

Baird

Outperform

downgrade

$395 -> $392

2025-12-16

Reason

Baird

Price Target

$395 -> $392

2025-12-16

downgrade

Outperform

Reason

Baird lowered the firm's price target on Cencora to $392 from $395 and keeps an Outperform rating on the shares. The firm updated its model following its announced acquisition of OneOncology.

Valuation Metrics

The current forward P/E ratio for Centene Corp (CNC.N) is 17.95, compared to its 5-year average forward P/E of 12.22. For a more detailed relative valuation and DCF analysis to assess Centene Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

12.22

Current PE

17.95

Overvalued PE

14.92

Undervalued PE

9.51

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

9.99

Current EV/EBITDA

16.41

Overvalued EV/EBITDA

12.67

Undervalued EV/EBITDA

7.32

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

0.26

Current PS

0.11

Overvalued PS

0.33

Undervalued PS

0.18

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CNC News & Events

Events Timeline

No data

News

7.5

01-07NASDAQ.COM

Cityblock Partners with Meridian to Serve 10,000 Medicaid Beneficiaries in Illinois

7.5

01-07PRnewswire

Cityblock Partners with Meridian to Serve 10,000 Medicaid Beneficiaries in Illinois

7.5

01-07Newsfilter

Cityblock Partners with Meridian to Serve 10,000 Medicaid Beneficiaries in Illinois

People Also Watch

Frequently Asked Questions

What is Centene Corp (CNC) stock price today?

The current price of CNC is 46.61 USD — it has decreased -0.66 % in the last trading day.

What is Centene Corp (CNC)'s business?

Centene Corporation is a healthcare company. The Company provides fully integrated services to government-sponsored and commercial healthcare programs, focusing on under-insured and uninsured individuals. Its segments include Medicaid, Medicare, Commercial and Other. Specifically, the Medicaid segment includes the Temporary Assistance for Needy Families (TANF) program, Medicaid Expansion programs, the Aged, Blind or Disabled (ABD) program, the Children's Health Insurance Program (CHIP), Long-Term Services and Supports (LTSS), Foster Care, Medicare-Medicaid Plans (MMP), which cover beneficiaries who are dually eligible for Medicaid and Medicare and other state-based programs. The Medicare segment includes Medicare Advantage, Medicare Supplement, Dual Eligible Special Needs Plans and Medicare Prescription Drug Plans. The Commercial segment includes the Health Insurance Marketplace product along with individual, small group, and large group commercial health insurance products.

What is the price predicton of CNC Stock?

What is Centene Corp (CNC)'s revenue for the last quarter?

Centene Corp revenue for the last quarter amounts to 49.69B USD, increased 18.24 % YoY.

What is Centene Corp (CNC)'s earnings per share (EPS) for the last quarter?

Centene Corp. EPS for the last quarter amounts to -13.50 USD, decreased -1092.65 % YoY.

What changes have occurred in the market's expectations for Centene Corp (CNC)'s fundamentals?

How many employees does Centene Corp (CNC). have?

Centene Corp (CNC) has 60500 emplpoyees as of January 10 2026.

What is Centene Corp (CNC) market cap?

Today CNC has the market capitalization of 22.91B USD.